Pharmacology of Recombinant or Genetically Engineered Drugs

Kamal Kishore, Pawan Krishan

Departments of Pharmacy, M.J.P. Rohilkhand University, Bareilly-243 006, Uttar Pradesh, 
Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala-147 002, Punjab, India

Address for correspondence: Dr. Kamal Kishore; E-mail: kamalbareilly@yahoo.co.in

ABSTRACT
Recombinant technology or genetic engineering is a modern method used for the synthesis of therapeutic agents. The central theme of recombinant technology is the process of “gene cloning” which consists of the production of a defined fragment of DNA and its propagation and amplification in a suitable host cell. Drugs developed by recombinant technology or genetic engineering are known as biologics, biopharmaceuticals, recombinant DNA expressed products, bioengineered, or genetically engineered drugs. A current list of various products developed by recombinant technology includes erythropoietin, coagulation modulators, enzymes, hormones, interferons, interleukins, granulocyte colony-stimulating factors, anti-rheumatoid drugs, and various other agents like TNF, becaplermin, hepatitis-B vaccine, antibodies etc. This article provides general as well as recent pharmacological information on different aspects of recombinant drugs that may be useful for their better understanding by users and health care professionals.

Key words: Biologics, erythropoietin, interferon, interleukins, insulin, thrombolytic enzymes

DOI: 10.4103/0975-1483.55747

INTRODUCTION

Drugs developed using living organisms with the help of biotechnology or genetic engineering are known as biologics, biopharmaceuticals, recombinant DNA expressed products, bioengineered, or genetically engineered drugs. The recombinant technique was developed by Cohen in 1973.[1] The general procedure starts from the identification of the gene responsible for the production of the desired product. The gene is isolated from human cells and inserted into other carrier or vector cells like bacteria (Echerichia coli) or yeast (Saccharomyces cerevisiae, Hansenula polymorpha, Pichia pastoris) that proliferate and produce large amounts of the desired product.[2] The central theme of recombinant DNA technology is the process of “gene cloning” which consists of the production of a defined fragment of DNA and its propagation and amplification in a suitable host cell. Recombinant technology was only possible after the discovery of restriction endonucleases, the enzymes used as cutters for a desired segment[3] of genes known as recognition sequences. There are various other enzymes that have great value in recombinant technology such as DNA polymerases, ligases, kinases, alkaline phosphatases, and nucleases.[4] For thousands of years, living microorganisms have been used to produce gases, leaven bread, ferment alcoholic liquids, and for other desired by-products, but their use in recombinant DNA technology is often described as a relatively new science.[5] Recombinant technology, thus, is a new method for the development of drugs and other life-saving products that involves the blending of discoveries in molecular biology, DNA alteration, gene splicing, immunology,
and immunopharmacology. Now a days, various human diseases are treated with the help of drugs developed by recombinant technology, such as erythropoietin, coagulation modulators, enzymes, hormones, interferons, interleukins, granulocyte colony-stimulating factors, anti-rheumatoid drugs, and various other agents like Tumor necrosis factor (TNF), becaplermin, hepatitis-B vaccine, antibodies etc. This article provides general as well as recent pharmacological information on different aspects like a brief description of recombinant products, pharmacological actions, mechanism of action, adverse effects, doses, contraindications, interactions and therapeutic applications. The pharmacological information of bio-engineered products may be useful for better understanding by users and professionals in the medical and health-related sciences.

MANUFACTURING PROCESS FOR RECOMBINANT PRODUCTS

The following steps are involved in the production of recombinant products:

Extraction of the DNA from a donor organism and the plasmid from bacteria
\[\downarrow\]
Cleaved with restriction endonucleases
\[\downarrow\]
Joined to form a recombinant DNA molecule or vector
\[\downarrow\]
Insert this vector into host cell or expression system (E. coli or Yeast)
\[\downarrow\]
Multiplication of recombinant DNA molecules
\[\downarrow\]
Formation of clone
\[\downarrow\]
Scale-up (harvesting or fermentation) of cell to produce recombinant drugs
\[\downarrow\]
Purification (centrifugation or filtration)
\[\downarrow\]
Preformulation
\[\downarrow\]
Preclinical studies (animal testing)
\[\downarrow\]
Clinical studies (human testing)
\[\downarrow\]
Final product

CLASSIFICATION OF RECOMBINANT PRODUCTS

The following products or biologics are obtained by recombinant or genetic engineering technology:

(I) Recombinant erythropoietin
Epoetin-α
Epoetin-β
Epoetin-ω
Darbepoetin-α

(II) Recombinant blood coagulation modulators
(a) Coagulants
Factor-VII A
Factor-VIII
Factor-IX
(b) Anticoagulants
Lepirudin
Desirudin
Drotecogin alfa

(III) Recombinant enzymes
(a) Thrombolytic enzymes
Alteplase
Anistreplase
Duteplase
Reteplase
Saruplase
Streptase or streptokinase
Tenecteplase
Tissue plasminogen activator
Urokinase
(b) Therapeutic enzymes
Agalsidase beta
Aeromonas aminopeptidase
Alpha-glactosidase-A
Dornase alpha
Imiglucerase or glucocerebrosidase or alglucerase
Laronidase or alpha-L-iduronidase
Galsulfase or N-acetylgalactosamine-4-sulfatase

(IV) Recombinant hormones
(a) Insulin and its analogs
Human insulin
Insulin aspart
Insulin glargine
Insulin lispro
Insulin glulisine
Insulin-like growth factor-I
Insulin-like growth factor-II

(b) Growth hormone and its analogs
Growth hormone
Growth hormone (ovine)
Growth hormone binding protein
Pharmacology of recombinant drugs

Growth hormone-20K
Somatrem
Somatropin
Sermorelin

(c) Gonadotropins
Recombinant follitropin-α
Recombinant follitropin-β
Recombinant chorionic gonadotropin
Follicle-stimulating hormone
Luteinizing hormone

(d) Other hormones
Calcitonin
Glucagon

(V) Recombinant interferons
Interferon alfa-2a
Interferon alfa-2b
Interferon beta-1a
Interferon beta-1b
Interferon-gamma-1a
Interferon-gamma-1b
Interferons-ω
Consensus interferon

(VI) Recombinant interleukins
Interleukin-1 alpha
Interleukin-1 beta
Interleukin-2 (aldesleukin)
Interleukin-3
Interleukin-4
Interleukin-10
Interleukin-11 (oprelvekin)
Interleukin-13
Interleukin-15
Interleukin-17
Interleukin-18

(VII) Recombinant granulocyte colony stimulating factors
Filgrastim
Lenograstim
Molgramostim
Sargramostim
Regrasmostim
Pegfilgrastim

(VIII) Recombinant anti-rheumatoid agents
Infliximab
Adalimumab
Basiliximab
Daclizumab
Anakinra
Etanercept

(IX) Miscellaneous agents
Recombinant antibodies

Recombinant albumin
Fc purified recombinant protein
Becaplermin
Beta-nerve growth factor
Bone morphogenetic protein-2
Brain-derived neurotrophic factor
Ciliary neurotrophic factor
Chymosin
Endostatin human
Enteropeptidase/Enterokinase
Epidermal growth factors
Fibroblast growth factors
Hepatitis-B vaccine
Hepatocyte growth factor
Influenza A, nucleoprotein, recombinant protein
Lung surfactant protein
Relaxin
TNF
Recombinant vaccines
α-antitrypsin
Thrombopoietin

PHARMACOLOGY OF INDIVIDUAL PRODUCTS

Recombinant erythropoietin

Erythropoietin[6] is a 165 amino acid glycoprotein hormone that is synthesized naturally in the kidney and the liver but is now prepared by recombinant technology. It stimulates erythrocyte formation and is available as epoetin-α, epoetin-β, and darbepoetin-α. **Mechanism of action:** It stimulates proliferation and differentiation of erythrocytes.

**Dose:** 5-100 units/kg/s.c. or i.v./three times a week.

**Adverse effects:** Allergic reaction, deficiency of iron and folic acid, disorientation, encephalopathy, flu-like symptoms, headache, mild hypertension, seizures, and thrombosis.

**Uses:** It is preferred in cases of anemia due to AIDS, cancer chemotherapy, chronic renal failure, and anemia in premature babies. It is also useful in hematopoietic disorders and is used to increase the benefits of autologous blood transfusion.

Recombinant blood coagulation modulators

**Coagulants[7]**

Factor-VII A is a unique hemostatic agent containing 406 amino acids[8,9] that is supposed to activate the extrinsic pathway of the coagulation cascade.[10,11] **Dose:** 150-500 μg/kg of body weight.

**Adverse effects:** Factor VIIa may cause adverse effects such as pyrexia, hemorrhage, injection site reactions, arthralgia, headache, hypertension, nausea, vomiting, pain, edema, and rashes.

**Uses:** It is preferred in cases of hemophilia-A and B and in patients with congenital and acquired bleeding abnormalities.
Factor-VIII is an endogenous glycoprotein coagulating factor that is necessary for blood clotting and hemostasis. It is a cofactor essential for factor IX to activate factor X in the intrinsic pathway. It is a 1438 amino acid peptide that is produced in CHO cells. Deficiency of factor VIII causes a common inherited bleeding disorder known as hemophilia-A. A D M E: It is administered intravenously; its t½ is about 12 hours. D ose 10-50 IU/kg i.v. every 2-3 days. A d v e r s e e f f e c t s: Factor VIII may cause adverse effects like febrile reactions, angioedema, flushing, Urticaria, light-headedness, visual disturbances, nausea, and vomiting. U s e s: It is preferred in cases of prevention of bleeding during surgery in patients with hemophilia-A.

Factor-IX is a polypeptide containing 415 amino acids; it is a vitamin K-dependent coagulation factor that is synthesized in the liver or by recombinant technology. M e c h a n i s m o f a c t i o n: Factor IX activated by factor IXa, in combination with factor VIII, activates factor X to Xa and leads to the conversion of prothrombin to thrombin and the formation of a fibrin clot. D ose 75 IU/kg i.v. infusion. A d v e r s e e f f e c t s: Factor IX may cause adverse effects like headache, fever, chills, flushing, burning at injection site, tingling, hives, lethargy, nausea, and vomiting. U s e s: It is preferred in bleeding conditions such as hemophilia-B.

A n t i c o a g u l a n t s

Lepirudin[13] and Disirudin[14] are thrombin-inhibiting agents, developed by recombinant technology and are also known as derivatives of hirudin. P r e c a u t i o n s: used cautiously in patients with renal failure. M e c h a n i s m o f a c t i o n: They directly bind to clot-bound and fluid-phase thrombin. D ose 30 mg/kg i.v./day. U s e s: They are preferred in cases of heparin-induced thrombocytopenia and deep vein thrombosis.

Drotrecogin alfa is a recombinant form of human activated protein-C used as an anticoagulant and anti-inflammatory agent. M e c h a n i s m o f a c t i o n: Inhibition of coagulation by proteolytic inactivation of factors Va and VIIIa. D ose 24 mg/kg/h for a maximum of 96 hours. A d v e r s e e f f e c t s: Drotrecogin alfa therapy may cause bleeding. U s e s: It is preferred for the treatment of severe sepsis.

R e c o m b i n a n t e n z y m e s

T h r o m b o l y t i c e n z y m e s

Alteplase[15] is an enzyme that catalyzes tissue plasminogen to plasmin and is commonly used to prevent clot-related myocardial disorders. M e c h a n i s m o f a c t i o n: It dissolves blood clots by converting plasminogen into plasmin that digests fibrin, fibrinogen, and other proteins. I n t e r a c t i o n s: Its action accelerates in combination with heparin. C o n t r a i n d i c a t e d i n bleeding, defective homeostasis, trauma, surgical procedures, stroke, acute pericarditis, hypoglycemia and hyperglycemia. D o s e: 100 mg i.v. infusion. A d v e r s e e f f e c t s: Alteplase may cause adverse effects like nausea, vomiting, fever, arrhythmias, allergy, hypotension, intracranial hemorrhage, and GIT bleeding. U s e s: It is preferred in cases of angina pectoris, as an anticoagulant, intravascular thrombosis, ischemic diseases, myocardial infarction, pulmonary embolism, and to dissolve thrombi.

Tissue plasminogen activator is fibrin-selective but does not activate systemic plasminogen. It is synthesized by recombinant technology and is also obtained from cultured human melanoma cells. M e c h a n i s m o f a c t i o n: It induces fibrinolysis of the formed thrombus by preferentially activating plasminogen bound to fibrin. D o s e: 100 mg i.v./3 hours. U s e s: It is preferred in the treatment of deep vein thrombosis.

Streptase or streptokinase[14] is obtained from β-hemolytic Streptococci group-C. It combines with circulating plasminogen to form an activation complex, which then causes limited proteolysis of other plasminogen molecules to plasmin. Anthrostreptococcal antibodies present due to the initial dose of streptokinase make a loading dose necessary in the beginning. M e c h a n i s m o f a c t i o n: Streptokinase activates the conversion of plasminogen (profibrinolysin) into plasmin (fibrinolysin), which stimulates the conversion of fibrin (insoluble) into fibrin fragments (soluble). D o s e: 250,000 units followed by 100,000 units/hour for 1-3 days. C o n t r a i n d i c a t e d in active internal bleeding, bleeding diathesis, cerebral tumor. If hemostasis is important, pregnancy, previous cerebrovascular accident, recent cranial trauma, surgery within ten days, and uncontrolled hypertension. A d v e r s e e f f e c t s: Streptokinase may cause anaphylaxis, bronchospasm, hypersensitivity, fever, hypotension, and arrhythmias. U s e s: It is preferred in cases of acute arterial thromboembolism, acute myocardial infarction, acute thrombotic stroke, deep venous thrombosis, local thrombolysis in the anterior chamber of the eye, myocardial infarction, and unstable angina.

Urokinase[17] is a proteolytic but not antigenic, fibrin-selective, thrombolytic, or fibrinolytic agent. It is developed by recombinant technology as pro-urokinase and is also derived from the human kidney (is present in urine). It is converted to urokinase from pro-urokinase upon its binding to fibrin. M e c h a n i s m o f a c t i o n: It directly converts plasminogen into plasmin. C o n t r a i n d i c a t e d in bleeding risks, vascular aneurysm, recent cranial trauma, surgery within ten days, and uncontrolled hypertension. A d v e r s e e f f e c t s: Urokinase may cause fever, bleeding, GIT bleeding, and hemolytic stroke.
Tenecteplase is developed by the recombinant technique and is a human plasminogen and streptokinase activator complex. The anisoyl group is removed in blood by a hydrolytic deacylation process. A diverse effects: Tenecteplase may cause hypotension and allergy.

Anistreplase is a full-length, human, unglycosylated, single-chain polypeptide containing 411 amino acids, urokinase type plasminogen activator and also known as prourokinase. It is obtained by recombinant technology from E. coli. It is a fibrin-specific fibrinolytic agent and is effectively used for the treatment of thrombotic disorders such as acute myocardial infarction. A diverse effects: Anistreplase may cause hypotension and allergy.

Saruplase is a full-length, human, unglycosylated, single-chain polypeptide containing 411 amino acids, urokinase type plasminogen activator and also known as prourokinase. It is obtained by recombinant technology from E. coli. It is a fibrin-specific fibrinolytic agent and is effectively used for the treatment of thrombotic disorders such as acute myocardial infarction. A diverse effects: Saruplase may cause hypotension and allergy.

Therapeutic enzymes

Imiglucerase is administered as enzyme replacement therapy in Gaucher’s disease, a familial disorder affecting mainly the liver, spleen, bone marrow, and lymph nodes due to the deficiency of beta-glucocerebrosidase activity, leading to the accumulation of glucocerebrosidase in many body tissues. It improves hematological abnormalities, hepatosplenomegaly and quality of life in patients of Gaucher’s disease. Mechanism of action: It catalyzes the hydrolysis of glucocerebrosidase to glucose and ceramide. Dose: 60 units/kg/i.v. infusion/two weeks. A diverse effects: Imiglucerase may cause abdominal cramps, anorexia, diarrhea, dizziness, fatigue, fever, flushing, headache, hypotension, nausea, vomiting, tachycardia, and urticaria. Uses: It is preferred in the treatment of Gaucher’s disease.

Agalsidase beta is an enzyme used for the treatment of Fabry’s disease; a lysosomal storage disorder caused by a deficiency of alpha-galactosidase, leading to progressive accumulation of glycosphingolipids, particularly GL-3 in many body tissues. Mechanism of action: It provides an exogenous alpha-galactosidase-A, and catalyzes the hydrolysis of glycosphingolipids including GL-3. Dose: 1 mg/kg/i.v. infusion/two weeks for 20 weeks. A diverse effects: Agalsidase beta may cause nausea, vomiting, abdominal pain, abnormal tear secretion, anemia, bradycardia, dizziness, drowsiness, edema, fatigue, fever, headache, hypersensitivity reactions, hypertension, injection site pain, myalgia, palpitation, paraesthesia, proteinuria, tachycardia, tremors, and visual disturbances. Uses: It is preferred in the treatment of Fabry’s disease.

Laronidase is an enzyme used for the treatment of non-neurological manifestations of mucopolysaccharidosis-I, a lysosomal storage disorder caused by the deficiency of alpha-L-iduronidase. Dose: 0.58 mg/kg/i.v. infusion/once a week. A diverse effects: Laronidase may cause flushing, musculoskeletal pain, rashes, headache, and abdominal pain. Uses: It is preferred in non-neurological manifestations of mucopolysaccharidosis-I and to improve pulmonary functions.

Dornase alpha is an enzyme prepared from Chinese hamster ovary cells. It is a 260 amino acid, phosphorylated, recombinant human deoxyribonuclease-1 (rhDNase) or is a genetically engineered product of a naturally occurring human enzyme that breaks extracellular deoxyribonucleic acid or DNA. It is useful in the treatment of cystic fibrosis. Pharmacological actions: It reduces mucus viscosity in cystic fibrotic patients. Mechanism of action: Cleave extracellular DNA and reduces sputum viscosity. Precautions: Breast feeding mothers. Dose: 2.5 mg/OD or BD/inhaled by nebulizer. A diverse effects: Dornase alpha may cause chest pain, conjunctivitis, laryngitis, pharyngitis, rashes, urticaria, and voice changes. Uses: It is preferred in the treatment of cystic fibrosis.

Recombinant hormones

Insulin and its analogs

Insulin is a protein hormone produced by the β-cells of the Islets of Langerhans of the pancreas. It regulates the metabolism of carbohydrates, fats, and proteins. Lack of insulin or resistance to its action may causes diabetes mellitus. It lowers the blood glucose concentration by increasing the uptake of glucose into tissues, enhancing glycogen synthesis from glucose, and inhibition of glycogenogenesis. Sources of insulin: Human insulin is prepared by enzymatic modification of porcine insulin or by recombinant technology using E. coli. Routes for insulin administration: Intraperitoneally, implants, oral, nasal, rectal, and inhalation. Insulin delivery devices: External artificial pancreas, implantable pumps, insulin pumps, insulin syringes, jet injectors, and pen devices. Mechanism
Growth hormones and their analogs

Growth hormones and their analogs are synthesized by recombinant technology, and are commonly used as growth-promoting agents. These agents are not effective in bone disorders, cardiac diseases, cartilage disorders, Down syndrome, families of short stature, GIT problems, and renal complications. They are available as somatrem, somatropin, and sermorelin. These agents are recommended for the treatment of complications due to the deficiency of growth hormone. Growth hormone deficiency may occur due to skull fracture, excessive exposure to radiation, cancer disease, and due to intracranial infections like tuberculosis or meningitis. Adverse effects: Insulin may cause hypoglycemia, local irritation, local hypertrophy, hypersensitivity, and weight gain or obesity. It is preferred in diabetes due to pancreatic disease, diabetes, ketoacidosis or diabetic coma, hyperkalemia, improving appetite and body weight, and schizophrenia. It can also be used to test the completeness of growth hormone deficiency, in the treatment of diabetes mellitus, particularly IDDM, and an insulin + glucose infusion may be used in-cyclic vomiting, hyperemesis gravidam, anorexia, and acute alcoholism.

Mechanism of action: Insulin interacts with insulin receptors located on the liver and the fat cells, and enhances the transport of glucose from the blood into cells by increasing the activity of glucose transporters. ADME: Insulin is administered subcutaneously, degraded by proteolytic enzymes in the liver, kidney, and muscles, and its t1/2 is 5-9 min. Interactions: Alcohol and β-blockers produce a synergistic hypoglycemic effect. Contraindicated with β-blockers which mask the hypoglycemic effect in diabetic patients who are on insulin therapy. Adverse effects: Insulin may cause hypoglycemia, local irritation, local hypertrophy, hypersensitivity, and weight gain or obesity. It is preferred in diabetes due to pancreatic disease, diabetes, ketoacidosis or diabetic coma, hyperkalemia, improving appetite and body weight, and schizophrenia. It can also be used to test the completeness of growth hormone deficiency, in the treatment of diabetes mellitus, particularly IDDM, and an insulin + glucose infusion may be used in-cyclic vomiting, hyperemesis gravidam, anorexia, and acute alcoholism.

Growth hormones and their analogs[25]

Growth hormones and their analogs are synthesized by recombinant technology, and are commonly used as growth-promoting agents. These agents are not effective in bone disorders, cardiac diseases, cartilage disorders, Down syndrome, families of short stature, GIT problems, and renal complications. They are available as somatrem, somatropin, and sermorelin. These agents are recommended for the treatment of complications due to the deficiency of growth hormone. Growth hormone deficiency may occur due to skull fracture, excessive exposure to radiation, cancer disease, and due to intracranial infections like tuberculosis or meningitis. Adverse effects: Insulin may cause hypoglycemia, local irritation, local hypertrophy, hypersensitivity, and weight gain or obesity. It is preferred in diabetes due to pancreatic disease, diabetes, ketoacidosis or diabetic coma, hyperkalemia, improving appetite and body weight, and schizophrenia. It can also be used to test the completeness of growth hormone deficiency, in the treatment of diabetes mellitus, particularly IDDM, and an insulin + glucose infusion may be used in-cyclic vomiting, hyperemesis gravidam, anorexia, and acute alcoholism.

Mechanism of action: Insulin interacts with insulin receptors located on the liver and the fat cells, and enhances the transport of glucose from the blood into cells by increasing the activity of glucose transporters. ADME: Insulin is administered subcutaneously, degraded by proteolytic enzymes in the liver, kidney, and muscles, and its t1/2 is 5-9 min. Interactions: Alcohol and β-blockers produce a synergistic hypoglycemic effect. Contraindicated with β-blockers which mask the hypoglycemic effect in diabetic patients who are on insulin therapy. Adverse effects: Insulin may cause hypoglycemia, local irritation, local hypertrophy, hypersensitivity, and weight gain or obesity. It is preferred in diabetes due to pancreatic disease, diabetes, ketoacidosis or diabetic coma, hyperkalemia, improving appetite and body weight, and schizophrenia. It can also be used to test the completeness of growth hormone deficiency, in the treatment of diabetes mellitus, particularly IDDM, and an insulin + glucose infusion may be used in-cyclic vomiting, hyperemesis gravidam, anorexia, and acute alcoholism.

Gonadotropins[26]

(i) Recombinant human growth hormone, (ii) Menotropins (FSH+LH) (obtained from urine of menopausal women)-Recombinant follitropin-α and follitropin-β, (iii) Urofollitropin or menotropin (Pure FSH), and (iv) Human chorionic gonadotropin (obtained from urine of pregnant women). Recombinant choriogonadotropin-α and luteinizing hormone. Uses: They are preferred in reproductive endocrinology, to restore fertility in males and females, and diagnosis of pregnancy, time of ovulation and several male and female reproductive disorders.

Interferons are naturally occurring, inducible, small glycoproteins or cytokines, host-specific, broad-spectrum, potent, synthetic antiviral agents. They may also be produced by all body cells in response to inducers such as attenuated measles, microbial extracts, viruses, and anionic polysaccharides. They induce protein kinases, oligo(isoadenylate synthetase, and phosphodiesterase enzymes. They can now be prepared by recombinant and cell culture techniques. They are nonspecific replication inhibitors of DNA and RNA viruses. The following types of interferons have been developed: Interferon α-2a,
interferon alfa-2b, interferon beta-1a, interferon beta-1b, interferon-gamma-1a, interferon-gamma-1b, interferons-ω, and consensus interferon. **Mechanism of action:** They block viral replication by inhibiting the translation of viral mRNA into viral proteins and suppress cell proliferation. **ADME:** They are administered i.m. or s.c. have a half short $t_{1/2}$ and a small amount have been found to enter cerebrospinal fluid. **Dose:** 3-10 MU/i.v. infusion/TDS/week. **Adverse effects:** Interferons may cause alopecia, anemia, bone marrow depression, cardiovascular disorders, depression, fatigue, fever, GIT disturbances, headache, hepatotoxicity, hyperglycemia, hypersensitivity reactions, hypotension, influenza-like symptoms, leucopenia, myalgias, myelosuppression, nephrotoxicity, neutropenia, suicidal behavior, thrombocytopenia, and weakness. **Uses:** α-interferon is used in hepatitis, AIDS, herpes simplex, herpes zoster, and certain types of cancers, hairy cell leukemia, and viral infections. β-interferons are used in sclerosis (hardening of blood vessels). Interferon-γ has been used in rheumatoid arthritis, chronic granulocytosis, hepatitis, leishmaniasis, leprosy, and psoriasis. Consensus interferon is used in hepatitis-C, neoplastic disorders, and infectious complications.

**Recombinant interleukins**

Aldesleukin[29] is an interleukin-2 obtained from cultures of *E. coli* and is available in two forms: Alpha and beta. **Mechanism of action:** It stimulates the natural killer cells, T and B cells, TC cells, and enhances cellular immunity. **Dose:** 600,000 units/kg/eight hourly for five days. **Adverse effects:** Aldesleukin may cause nausea, vomiting, diarrhea, fever, capillary leak syndrome, hypotension, arrhythmias, peripheral edema, prerenal azotemia, thrombocytopenia, decreased tissue perfusion, confusion, and can reduce concomitant infection. **Uses:** It is preferred in the treatment of metastatic renal cell carcinoma and melanoma.

Oprelvekin is a recombinant human interleukin-11 cytokine, consisting of 177 amino acids. It stimulates megakaryocytes and their precursors in the bone marrow and thus, prevents severe thrombocytopenia and decreases the need for platelet transfusions in cancer patients receiving highly myelosuppressive chemotherapy.

**Pharmacological actions:** It stimulates the growth of multiple lymphoid and myeloid cells and consequently, enhances platelet and neutrophil counts. **Mechanism of action:** Suppresses chemotherapy-induced thrombocytopenia by stimulating megakaryocytes and their precursors in the bone marrow. **ADME:** It is administered subcutaneously and its $t_{1/2}$ is seven hours. **Dose:** 25-50 μg/kg/s.c./day. **Adverse effects:** Oprelvekin may cause arthralgia, dizziness, headache, anemia, dyspnea, hypokalemia, atrial arrhythmia, fatigue, immunogenicity, myalgia, palpitations, and peripheral edema. **Uses:** It is preferred in the treatment of chemotherapy-induced thrombocytopenia.

**Recombinant granulocyte colony-stimulating factors[30-31]**

These are naturally occurring or synthetic glycoproteins that stimulate the multiplication, differentiation, and actions of neutrophils, monocytes, and macrophages. They are useful in the treatment of aplastic anemia and AIDS.

Filgrastim[32] is a 175 amino acid, recombinant, human granulocyte colony-stimulating factor that enhances the synthesis of neutrophils. **Pharmacological actions:** It enhances neutrophil functions and production, increases phagocytosis, cytotoxic and antibody-dependent killing effect of neutrophils, and enhances bone marrow repopulation after high doses of chemotherapy, radiotherapy, and bone marrow transplants. It also mobilizes hematopoietic stem cells into peripheral blood. **Mechanism of action:** It stimulates proliferation and differentiation of neutrophils. **ADME:** It is administered as an s.c or i.v. infusion, 20 μg/kg for 30 minutes, $t_{1/2}$ is 3.5 hours. **Contraindicated in** severe congenital neutropenia. **Dose:** 5 μg/kg/s.c. or i.v./day. **Adverse effects:** Filgrastim may cause anemia, bone tenderness, and pain, breathlessness, cutaneous vasculitis, disuria, epistaxis, exacerbation of rheumatoid arthritis, fever, flushing, hepatomegaly, hypotension, increased uric acid, lethargy, mialgia, nausea, vomiting, osteoporosis, pericardial effusions, lowering of BP, skin rashes, splenic enlargement, tachycardia, thrombocytopenia, and urinary abnormalities. **Uses:** It is preferred in bone marrow suppression or myelosuppression during cancer chemotherapy, chemotherapy-induced neutropenia, cytotoxic-induced neutropenia in AIDS patients during zidovudine therapy, leucopenia, to increase neutrophil counts, to prevent infections, and to treat congenital, cyclic, and aplastic anemia-induced neutropenia.

Molgramostim is an unglycosylated, 127 amino acid, recombinant, human granulocyte macrophage colony-stimulating factor that is derived from *E. coli*. **Mechanism of action:** It stimulates the production of granulocytes and monocytes. **Dose:** 5-10 μg/kg/s.c./day. **Adverse effects:** Molgramostim may cause hypotension, flushing, bone pain, fever, musculoskeletal pain, and GIT disturbances. **Uses:** It is used to reduce the severity of neutropenia in patients on immunosuppressive therapy and to accelerate myeloid recovery in patients with bone marrow transplantation.
Sargramostim is a 127 amino acid glycoprotein that is produced in a yeast expression system. It enhances myeloid engraftment in autologous bone marrow transplantation, decreases the duration of antibiotic administration, and reduces the incidence of infections. It also enhances the proliferation and differentiation of neutrophils, eosinophils, monocytes, and macrophages. **ADME**: It is administered subcutaneously or intravenously, \( t_{1/2} \) is 2-3 hours. **Dose**: 125-500 \( \mu \)g/m\(^2\)/day/s.c or i.v. infusion. **Adverse effects**: Sargramostim may cause pleural and pericardial effusion, fever, hypotension, and immunosuppression during cancer chemotherapy.

**Recombinant antirheumatoid agents**

Etanercept is a genetically engineered, modified fusion protein that resembles the cell surface receptor to which TNF-alpha normally binds to exert its actions. It is thus, a cytokine-inhibiting agent, inhibiting tumor necrosis factor-alpha, and is hence, used in the treatment of idiopathic arthritis. **Mechanism of action**: Inhibition of inflammatory and immunoregulatory actions of TNF-alpha by blocking its interaction with cell surface receptors. **ADME**: It is administered subcutaneously, \( t_{1/2} \) is about 115 hours. **Dose**: 6 mg/s.c or i.v./OD/chemotherapy. **Adverse effects**: It is preferred in febrile neutropenia and infections in chemo patients.

Adalimumab is a human, recombinant, monoclonal antibody to TNF-alpha. It is similar to infliximab but less antigenic as it does not contain any foreign component. **Mechanism of action**: Inhibits T-cell and macrophage functions and the release of pro-inflammatory cytokines by occupying the membrane-bound TNF-alpha receptors. **ADME**: It is administered intravenously, \( t_{1/2} \) is 200 hours. **Precautions**: Caution may be taken when used in cases of hepatic impairment, renal impairment, heart failure and demyelinating CNS disorders. **Interactions**: Better results with methotrexate and live-attenuated vaccines. **Contraindicated** in severe infections like tuberculosis, pregnancy and breast feeding. **Dose**: 40 mg/0.8 ml/s.c./OD for two weeks. **Adverse effects**: It is preferred in the treatment of rheumatoid arthritis.

Infliximab is a chimeric monoclonal antibody that inhibits the pro-inflammatory cytokine, TNF-\( \alpha \). **Mechanism of action**: Inhibits T-cell and macrophage functions and the release of pro-inflammatory cytokines by occupying the membrane-bound TNF-alpha receptors. **ADME**: It is administered intravenously, \( t_{1/2} \) is 200 hours. **Precautions**: Caution may be taken when used in cases of hepatic impairment, renal impairment, heart failure and demyelinating CNS disorders. **Interactions**: Better results with methotrexate and live-attenuated vaccines. **Contraindicated** in severe infections like tuberculosis, pregnancy and breast feeding. **Dose**: 5 mg/kg/i.v. infusion/every eight weeks. **Adverse effects**: Infliximab may cause effects like agitation, alopecia, amnesia, anxiety, arrhythmias, arthralgia, bradycardia, cholecystitis, confusion, constipation, demyelinating disorders, diarrhea, diverticulitis, dizziness, drowsiness, dyspepsia, ecchymosis, endophthalmitis, fatigue, flushing, GIT hemorrhage, hematoma, hepatitis, hyperkeratosis, insomnia, interstitial pneumonitis or fibrosis, myalgia, palpitaiton, peripheral ischemia, rashes, seizures, skin pigmentation, sweating, syncope, vaginitis, and vasospasm. **Uses**: It is preferred in fistulating Crohn's disease, rheumatoid arthritis, and severe active Crohn's disease.

Basiliximab and daclizumab are immunosuppressive, chimeric, monoclonal anti-CD50 antibodies produced by recombinant DNA technology. **Mechanism of action**: Block the alpha-chain of the interleukin-2 receptor located on the surface of activated T-cells. **Interactions**: Better results when given with glucocorticoids, cyclosporine, or azathioprine. **Dose**: 20 mg/twice/hour before transplantation surgery and 20 mg again on day 4 following transplantation. **Adverse effects**: It is preferred in the treatment of rheumatoid arthritis.
preferred for the prophylaxis of organ transplants like liver and heart rejection reactions.

Miscellaneous agents

Becaplermin[21] is a recombinant human platelet-derived growth factor for the treatment of full-thickness neuropathic and diabetic ulcers. It is applied topically as a thin layer daily and covered with gauze dressing moistened with physiological saline for a maximum duration of treatment 20 weeks. **Precautions:** Avoid on sites with infection, malignancy, peripheral arteriopathy, osteomyelitis. **Dose:** 0.01% gel/topically. **A diverse effects:** Becaplermin may cause irritation, bullous eruption, and edema. **Uses:** It is used for the treatment of diabetic pressure ulcers.

Hepatitis-B vaccine[37] contains inactivated hepatitis-B virus surface antigen adsorbed on aluminum hydroxide. **Dose:** 1 ml/i.m./repeated one month and six months later. **A diverse effects:** Hepatitis-B vaccine may cause abdominal pain or cramps, agitation, anorexia, arthralgia, asthma, back pain, bronchospasm, chills weakness, constipation, disturbed liver functions, dizziness, ecchymosis, erythema, fatigue, fever, flushing, headache, hypersensitivity, hypotension, influenza-like symptoms, insomnia, lymphadenopathy, malaise, myalgia, nausea, vomiting, pain, palpitation, pruritis, rashes, soreness and induration at the injection site, stiffness in arms, sweating, tachycardia, tingling, and urticaria. **Uses:** It is used to immunize people who are directly involved with the blood or saliva of patients and for passive immunization by vaccination with hepatitis-B immunoglobulin.

Thrombopoietin is a 332 amino acid, high molecular weight glycoprotein produced by hepatocytes and is a primary regulator of platelet production. It is available in two forms: Human megakaryocyte and development factor, and human thrombopoietin. Recombinant human thrombopoietin also reduces the duration of thrombocytopenia and the need for platelet transfusion in cancer patients receiving carboplatin or cyclophosphamide. **Pharmacological actions:** Stimulates the growth of platelets. **A diverse effects:** Therapy with thrombopoietin may cause immunogenicity. **Uses:** It is preferred in thrombocytopenia and thrombocytopenia due to cancer chemotherapy and radiation-induced myelosuppression

**CONCLUSION**

Recombinant technology or genetic engineering is a modern method used for the synthesis of therapeutic agents. The technique has provided the means to develop many biologically effective therapeutic agents. Recombinant products, biopharmaceuticals, biologics, or genetically engineered drugs are produced using this technology by inserting the desired product isolated from human cells into other carriers or vector cells. Some of the products of recombinant technology are of human origin including erythropoietin, coagulation modulators, enzymes, hormones, interferons, interleukins, granulocyte colony-stimulating factors, antirheumatoid drugs, and various other agents like TNF, becaplermin, hepatitis-B vaccine, antibodies etc. They are proteins and nucleic acids and are very specific, safe and pure agents.

**REFERENCES**


Source of Support: Nil, Conflict of Interest: None declared.

OTHER ACTIVITIES - INPHARM

- **Young Pharmacists Group of India** – InPharm is the main association of young pharmacists in India (Age upper limit - 35 yrs) and aims at improving the knowledge of young Pharmacists. YPGI - InPharm exists to stimulate the exchanges and networking between young Pharmacists, to foster the co-operation and the sharing of best practices amongst them, particularly in the field of pharmaceutical education and research.

- **Global Pharmacy Students Federation** (GPSF) is one of the non-profit global network that enables students and youth to interact with students of other countries to collaborate on projects/studies that enhance pharmaceutical learning and make a difference in the world.

- **The mission of the Women Pharmacists Group** (WPG-InPharm) is to help & develop outstanding women pharmacists, who impact with knowledge and integrity. The WPG-InPharm group is dedicated to support women through education and research. In addition, WPG-InPharm provides an atmosphere for personal growth and social networking for women pharmacists. WPG-InPharm recognizes, and works to eliminate, the multiple levels of oppression that act in society.

**Author Help: Reference checking facility**

The manuscript system (www.journalonweb.com) allows the authors to check and verify the accuracy and style of references. The tool checks the references with PubMed as per a predefined style. Authors are encouraged to use this facility, before submitting articles to the journal.

- The style as well as bibliographic elements should be 100% accurate, to help get the references verified from the system. Even a single spelling error or addition of issue number/month of publication will lead to an error when verifying the reference.

- Example of a correct style


- Only the references from journals indexed in PubMed will be checked.

- Enter each reference in new line, without a serial number.

- Add up to a maximum of 15 references at a time.

- If the reference is correct for its bibliographic elements and punctuations, it will be shown as CORRECT and a link to the correct article in PubMed will be given.

- If any of the bibliographic elements are missing, incorrect or extra (such as issue number), it will be shown as INCORRECT and link to possible articles in PubMed will be given.